Tamoxifen for breast cancer prophylaxis: where to from here?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1219, 2000-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?

By Lazaro A.

PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. : 943-961

Adis International

Access to resources Recommend Favorite

Therapy for Osteosarcoma: Where Do We Go From Here?

By Chou Alexander J.

Pediatric Drugs, Vol. 10, Iss. 5, 2008-01 ,pp. : 315-327

Adis International

Access to resources Recommend Favorite

Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?

By Giembycz M.A.

Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. : 193-212

Adis International

Access to resources Recommend Favorite

Supplementary protection certificates on reformulations and new uses after Neurim: where do we go from here?

By Duncan Garreth

Pharmaceutical Patent Analyst, Vol. 2, Iss. 2, 2013-03 ,pp. : 157-159

Future Science

Access to resources Recommend Favorite

Tamoxifen plus chemotherapy worth it in early breast cancer?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 354, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite